A new drug has just been approved for use in Australia. SITAGLIPTIN (Januvia) is an oral drug for type 2 Diabetes mellitus. It is a new class of drug, a dipeptidyl peptidase (DPP-4) inhibitor. Sitagliptin is an 'incretin enhancer' that increases the levels of active incretin by inhibiting their metabolism by DPP-4, thus prolonging their effect in stimulating insulin release and decreasing glucagon secretion.

The first meeting of the Fellowship Affairs Committee was held on Friday, 15 August 2008. Chaired by Dr Margaret Cowling, the Committee oversees all matters directly pertinent to Fellows, including CPD, annual scientific meetings, Regional CME and SIG events, communications and professional issues

You might wonder whether turning off the lights when not required actually saves energy. Thanks to the efforts of College staff, we have saved a massive 15 per cent greenhouse gas emissions over the last six months compared to last year. A lot of this can be attributed to turning off lights and switching to energy efficient flourescent light globes. The impact has been significant.